1h Free Analyst Time
The anti-obesity drugs market is forecast to grow by USD 18.33 billion during 2023-2028, accelerating at a CAGR of 14.44% during the forecast period. The report on the anti-obesity drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing obese population, use of bariatric surgery limited for morbid obesity, and limited number of approved drugs.
The anti-obesity drugs market is segmented as below:
By Type
- Class III anti-obesity drugs
- Class II anti-obesity drugs
- Class I anti-obesity drugs
By Drug Class
- Peripherally acting drugs
- Centrally acting drugs
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the anti-obesity drugs market covers the following areas:
- Anti-obesity drugs market sizing
- Anti-obesity drugs market forecast
- Anti-obesity drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global anti-obesity drugs market: Alvogen Iceland ehf, Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Empros Pharma AB, ERX Pharmaceuticals Inc., Gelesis Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., LG Chem Ltd., Novo Nordisk AS, Rhythm Pharmaceuticals Inc., SCOHIA PHARMA Inc., VIVUS LLC, and Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is research on drugs that target both obesity and type 2 diabetes mellitus."
According to the report, one of the major drivers for this market is the growing obese population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alvogen Iceland ehf
- Amgen Inc.
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Eli Lilly and Co.
- Empros Pharma AB
- ERX Pharmaceuticals Inc.
- Gelesis Inc.
- GlaxoSmithKline Plc
- Innovent Biologics Inc.
- LG Chem Ltd.
- Novo Nordisk AS
- Rhythm Pharmaceuticals Inc.
- SCOHIA PHARMA Inc.
- VIVUS LLC
- Zydus Lifesciences Ltd.
